Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
General Rheumatology
•
Infectious Disease
•
Vaccines
•
Shingles vaccination
•
Allergy & Immunology
•
Primary Immunodeficiency
•
Primary Care
Would you advise an immunocompromised patient that developed a dermatomal rash after the first recombinant zoster vaccine to receive the second dose?
Related Questions
Can inflammatory arthritis develop in patients with a history of chronic hepatitis B?
How would you approach diagnosis of a patient with recurrent episodes of abdominal pain, severe myalgias, low grade fevers and urticaria?
How do you approach vaccination, particularly the use of live vaccines such as yellow fever, in a patient with rheumatoid arthritis receiving a TNF inhibitor who is planning travel to Africa?
What are your practice recommendations regarding live vaccinations in infants/children of women who are currently on DMARDs and are breastfeeding?
How do you approach management of DMARDs and biologics in a patient with active RA, but frequent recurrent simple UTIs?
Is there any indication for IVIG in immunocompromised patients with only decreased IgM and/or IgA levels?
Is there any value to IgG subclasses in assessing immune deficiency in a patient with normal IgG levels?
In light of recent measles outbreaks, have you adjusted your vaccination counseling or preventive strategies for adult immunocompromised patients?
Is it better to give dose 2 of the mRNA 2024-2025 Covid-19 vaccine at month 2 or month 6 after dose 1 in moderately immunocompromised patients?
Are there specific conventional DMARDs and/or biologics that are contraindicated in patients with alpha-gal allergy?
